biostudies-literatureAragon-Herrera APredoctoral research grant from the PFIS Program of the Spanish Ministry of Science and Instituto de Salud Carlos III (Spain)Axencia Galega de Innovación (GAIN): Axudas do programa de consolidación e estruturación de unidades de investigación competitivasXunta de GaliciaPFIS Program of the Spanish Ministry of Science and Instituto de Salud Carlos IIINational Institute of Health “Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III” Madrid, SpainAxencia Galega de InnovaciónEuropean Regional Development Fund (FEDER) and European Union framework MSCA-RISE-H2020 ProgrammePredoctoral research grant from Xunta de GaliciaNational Institute of Health "Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III" Madrid, Spain1021https://www.ebi.ac.uk/biostudies/studies/S-EPMC9317583biostudies-literatureUnknown12(7)The pleiotropic hormone relaxin-2 plays a pivotal role in the physiology and pathology of the cardiovascular system. Relaxin-2 exerts relevant regulatory functions in cardiovascular tissues through the specific receptor relaxin family peptide receptor 1 (RXFP1) in the regulation of cardiac metabolism; the induction of vasodilatation; the reversion of fibrosis and hypertrophy; the reduction of inflammation, oxidative stress, and apoptosis; and the stimulation of angiogenesis, with inotropic and chronotropic effects as well. Recent preclinical and clinical outcomes have encouraged the potential use of relaxin-2 (or its recombinant form, known as serelaxin) as a therapeutic strategy during cardiac injury and/or in patients suffering from different cardiovascular disarrangements, especially heJournal of personalized medicineRelaxin-2 as a Potential Biomarker in Cardiovascular Diseases.PMC9317583PI21/01145, RETICS Programme RD16/0012/0014 and CIBER de Enfermedades Cardiovascula-res (CIBERCV)734899Project number 734899Not applicablePI21/01145RD16/0012/0014GPC IN607B 2021 108Lago FRosello-Lleti EMorana-Fernandez SGualillo OGonzalez-Juanatey JRPortoles MAragon-Herrera AFeijoo-Bandin STarazon EAnido-Varela LfalseRelaxin-2 as a Potential Biomarker in Cardiovascular Diseases.The pleiotropic hormone relaxin-2 plays a pivotal role in the physiology and pathology of the cardiovascular system. Relaxin-2 exerts relevant regulatory functions in cardiovascular tissues through the specific receptor relaxin family peptide receptor 1 (RXFP1) in the regulation of cardiac metabolism; the induction of vasodilatation; the reversion of fibrosis and hypertrophy; the reduction of inflammation, oxidative stress, and apoptosis; and the stimulation of angiogenesis, with inotropic and chronotropic effects as well. Recent preclinical and clinical outcomes have encouraged the potential use of relaxin-2 (or its recombinant form, known as serelaxin) as a therapeutic strategy during cardiac injury and/or in patients suffering from different cardiovascular disarrangements, especially he2022-01-01T00:00:00Z2022 Jun2025-04-25T16:52:41.693Z2022-08-06T22:42:03.644ZS-EPMC93175833588751710.3390/jpm12071021